Phenotypic resistance of resistant strains of HIV type-1 subtype B in China

Chinese Medical Journal

Volumn 119, Issue 23, 2006, Pages 1972-1977

  Li, Jue ^a   Lu, Jun Feng ^b   Dong, Hua Huang ^a   Bao, Zuo Yi ^a   Liu, Si Yang ^a   Li, Han Ping ^a   Zhuang, Dao Min ^a   Liu, Yong Jian ^a   Li, Hong ^c   Wang, Zhe ^c   Wu, Hao ^b   Li, Jing Yun ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Drug resistance; Genotype; Human immunodeficiency virus type 1; Phenotype

Indexed keywords

DELAVIRDINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ARTICLE; CHINA; CONTROLLED STUDY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; NONHUMAN; PHENOTYPE; PREDICTION; VIRUS ISOLATION; VIRUS RESISTANCE; VIRUS STRAIN; ANTIBIOTIC RESISTANCE; DRUG EFFECT; GENETICS; MUTATION;

ANTI-RETROVIRAL AGENTS; CHINA; DRUG RESISTANCE, VIRAL; HIV-1; HUMANS; MUTATION; PHENOTYPE;

EID: 33847123256     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200612010-00006     Document Type: Article

References (22)

1. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5: 41-48.
2. Haubrich R, Demeter L. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. J Acquir Immune Defic Syndr 2001; 26 Suppl 1: s51-s59.
3. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195-2199.
4. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science 1998; 280; 18711873.
5. Vandamme AM, Van Laethem K, De Clerq E. Managing resistance to anti-HIV drugs: an important consideration for effective disease management. Drugs 1999; 57: 337-361.
6. Baxter JD, Mayers DN, Wentworth JD, Neaton ML, Hoover MA, Winters SB, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000; 14: F83-F93.
7. Demeter L, Haubrich R. International perspectives on antiretroviral resistance. Phenotypic and genotypic resistance assays: methodology, reliability, and interpretations. J Acquir Immune Defic Syndr 2001; 26 Suppl 1: s3-s9.
8. Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998; 42: 269-276.
9. Walter H, Schmidt B, Kom K, Vandamme AM, Harrer T, Ubeda K. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J Clin Virol 1999; 13: 71-80.
10. Cohen C, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16: 579-588.
11. Zollner B, Feucht HH, Weitner L, Adam A, Laufs R. Drug-resistance genotyping in HIV-1 therapy. Lancet 1999; 354: 1120-1121.
12. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11: 215-221.
13. Palmer S, Shafer RW, Merigan TC. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 1999; 13: 661-667.
14. Whitcomb, JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188: 992-1000.
15. Beerenwinkel N, Schmidt B, Walter H, Kaiser R, Lengauer T, Hoffmann D, et al. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci USA 2002; 99: 8271-8276.
16. McLeod GX, McGrath JM, Ladd EA, Hammer SM. Didanosine and zidovudine resistence patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay. Antimicrob Agents Chemother 1992; 36: 920-925.
17. Haubrich R. Resistance and replication capacity assays: clinical utility and interpretation. Top HIV Med 2004; 12: 52-56.
18. Hertogs K, Bloor S, Kemp SD, Van den Eynde C, Alcorn TM, Pauwels R, et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor crossresistance: a survey of over 6000 samples. AIDS 2000; 14: 1203-1210.
19. Fonjung PN, Mpoudi JN, Torimiro GA, Alemnji LT, Eno EJ, Lyonga JN, et al. Human immunodeficiency virus type 1 group m protease in Cameroon: genetic diversity and protease inhibitor mutational features. J Clin Microbiol 2002; 40: 837-845.
20. Beerenwinkel N, Schmidt B, Walter H, Kaiser R, Lengauer T, Hoffmann D, et al. Geno2pheno: interpreting genotypic HIV drug resistance tests. IEEE Intellig Syst 2001; 16: 35-41.
21. Sevin AD, DeGruttola V, Nijhuis M, Schapiro JM, Foulkes AS, Para MF, et al. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333. J Infect Dis 2000; 182: 59-67.
22. Beerenwinkel N, Schmidt B, Walter H, Kaiser R, Lengauer T, Hoffmann D, et al. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci USA 2002; 99: 8271-8276.